Fresenius (ETR:FRE) Stock Upgrade
In a recent research report issued to clients on 18 December, DZ-Bank AG announced that they have decided to upgrade Fresenius (ETR:FRE) shares to a Buy.
From a total of 13 analysts covering Fresenius (ETR:FRE) stock, 6 rate it a ”Buy”, 0 a “Sell”, and 7 a ”Hold”. This means that 46% of the ratings are positive. The highest target price is €74 while the lowest target price is €60. The mean of all analyst targets is €66.04 with a 0.62% above today’s (€65.63) stock price. Fresenius was the topic of 24 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Jefferies maintained shares on December 17 with “Hold” rating. S&P Research upgraded shares to “Buy” rating and €74 target share price in a report from an October 30. Kepler Cheuvreux maintained FRE stock in a recent report from October 31 with “Hold” rating. Commerzbank upgraded the rating on September 15. Commerzbank has a “Add” rating and a €69 price target on shares. Finally, Warburg Research maintained the stock with “Hold” rating in a report issued on an October 31.
The stock increased 3.09% or EUR 1.97 on December 17, striking EUR 65.63. Approximately 1.85 million shares of stock traded hands or 66.67% up from the average. Fresenius SE & Co KGaA (ETR:FRE) has risen 6.00% since November 18, 2015 and is uptrending. It has outperformed by 8.26% the S&P500.
Fresenius SE & Co KGaA is a health care company. The company has a market cap of 35.49 billion EUR. It operates in the healthcare sector and offers services and products for dialysis, hospitals and outpatient medical care. It has 28.84 P/E ratio. It focuses on the hospital activities and offers engineering and services for hospitals and other health care facilities.